Business
Here’s Hinde Group’s Investment Thesis for Becton, Dickinson and Company (BDX)
Hinde Group, an investment management company, has released its third-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 14.37% (gross) and 13.93% (net) compared to 8.12% for the S&P 500 Total Return. The YTD return was 36.44% (gross) and 34.91% (Net) compared to 14.83% for the Index. The generative AI investment boom is a key reason the economy remains stable, and the stock market is optimistic despite ongoing political and economic challenges. You can check the fund’s top 5 holdings for its best picks for 2025.
In its third-quarter 2025 investor letter, Hinde Group highlighted stocks such as Becton, Dickinson and Company (NYSE:BDX). Becton, Dickinson and Company (NYSE:BDX) is a healthcare company that develops and manufactures medical supplies, devices, laboratory equipment, and diagnostic products. The one-month return of Becton, Dickinson and Company (NYSE:BDX) was 1.07%, and its shares lost 13.86% of their value over the last 52 weeks. On November 14, 2025, Becton, Dickinson and Company (NYSE:BDX) stock closed at $193.04 per share, with a market capitalization of $55.33 billion.
Hinde Group stated the following regarding Becton, Dickinson and Company (NYSE:BDX) in its third quarter 2025 investor letter:
“We initiated a long position in Becton, Dickinson and Company (NYSE:BDX) during the quarter. BDX is a special situation investment. It is our first new position since 2022.
